Delivery Order SPE2DB24D1205-SPE2DB25FDAGK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $20,839.40 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 12, 2025, with completion scheduled for August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a $13,120.39 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,819.81 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen (semaglutide injection) on August 25, 2025, with completion scheduled for August 26, 2025. This is a firm fixed price, non-set-aside contract with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $19,637.21 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pens on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,525.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen (semaglutide) on September 2, 2025, with a completion date of September 3, 2025. This non-competitive, non-set-aside delivery order will be fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $12,468.03 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. The contract was awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, under firm fixed pricing terms with no set-aside designation. Performance will take place at the vendor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $5,431.13 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract represents a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens with a ceiling value of $3,072.24. The contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 8, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.87 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $15,475.81 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDAGKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $370,595.28 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive portfolio of DLA contracts demonstrates its capacity to supply a diverse range of pharmaceutical products and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Zepbound, a GLP-1 receptor agonist indicated for weight management, aligns with the company's established track record of fulfilling federal medical supply requirements across multiple therapeutic domains through competitively awarded contracts with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $370.6k | 9/9/25 |